RVL Pharmaceuticals announced that its blepharoptosis (ptosis) drug Upneeq (oxymetazoline hydrochloride ophthalmic solution), 0.1% has been selected as the winner of a “Best  in Innovation” award in the 12th Annual Beauty Awards conducted by New Beauty, a Sandow Publication.

Upneeq was dubbed a Best in Innovation product for 2022 and “The Best Secret for Wide Awake Eyes” by the industry and consumer publication.

New Beauty Features Editor, Tatiana Bido, said of the non-surgical option to treat adults with acquired ptosis, “Upneeq is an instant eye-lifter for adults with acquired ptosis or low-lying eyelids. It's a true aesthetic innovation unlike anything else on the market.”

“We are thrilled to be acknowledged by New Beauty with an Innovation Award for Upneeq,” said JD Schaub, EVP & Chief Operating Officer. “We have full confidence that Upneeq, which is unmatched and emerging in the aesthetic marketplace, has the potential to address the significant unmet need in acquired ptosis therapy. Industry support and validation like this award from New Beauty is further proof of concept.”

Upneeq, which is composed of oxymetazoline hydrochloride ophthalmic solution at 0.1%, received its final FDA approval in July 2020, introducing to the market the only non-surgical therapeutic approved for the condition. Upneeq is a safe and effective, first-in-class treatment for acquired ptosis providing patients, eye care and all aesthetic providers a simple, convenient daily drop as of the national roll-out in January 2022.

In clinical trials, Upneeq demonstrated statistically significant improvements compared to placebo in both superior visual field and eyelid lift, as measured in two pivotal double-masked efficacy studies.  For more information visit www.upneeq.com.